NHS to pay 25% more for innovative drugs after UK–US zero-tariff deal
Strong Bearish
-100.0
Agreement could cost NHS an extra £3bn a year, industry sources estimateThe UK has agreed to pay 25% more for new medicines by 2035 as part of a US-UK drug pricing deal that will cost an estimated additional £3bn a year.The transatlantic agreement will also see the health service in England, which currently spends £14.4bn a year on innovative therapies, double the percentage of GDP it allocates to buying such products, from 0.3% to 0.6% over the next decade. Continue reading...
Pulse AI Analysis
Pulse analysis not available yet. Click "Get Pulse" above.
This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.
